Bertis to Present 10 Research
Outcomes at HUPO 2023,Including Development of Next-generation
Analysis Methodfor Proteomic Data- HUPO, one of the world's largest proteomics societies, is returning
to Korea for the first time in 16 years to be held at BEXCO, Busan from
September 17 to 21- Bertis joins as a major sponsor in the event which attracts over
1,000 scholars and key industry officials from 40 countries- Bertis presents 10 studies, including the development of
next-generation mass spectrometry and single-cell proteomic analysis, and highlights
its core technology framework, ‘ProteoID’, as well as nine essential
technologiesBertis, a company
specializing in the development of proteomics-based precision medicine
technology (led by CEOs Dong-young Noh and Seung-man
Han), announced on September 7 that it would
participate in ‘2023 HUPO, Human Proteome Organization’, one of the largest international academic gatherings in the field
of proteomics.
The event will take place from September 17 to 21 in Busan, Korea.HUPO 2023, themed 'Together Through
Proteomics,' is scheduled to be held at BEXCO in Busan. The event is expected
to draw over 1,000 researchers and prominent figures from more than 40
countries. This annual event, inaugurated in France in 2002, has been held
continuously, rotating through the Americas, Asia, Oceania, Europe, and Africa.
It now returns to Korea after 16 years since its last appearance in Seoul in
2007During the
event, Bertis will deliver presentations on 10 studies, including the development
of next-generation mass spectrometry and single-cell proteomic analysis
methodologies. The three main topics Bertis will cover in oral presentations
are ▲ Broad Target Scanning (BTS) - a pragmatic LC-MS acquisition method for
collecting population-scale real-world proteomics data ▲ Identification of
Secreted Unannotated Small ORF Microproteins from Adipocytes and in Plasma to
Elucidate Function of Novel Gene Product Proteins ▲ Spatial proteomic
approaches for triple-negative breast cancer on single-cell resolution. In
addition, the company will provide seven poster presentations on DeepMRM: Deep
learning-based object detection model for proteomics data, Exploring the Human
Aging Blood Proteome, and others.
<Image> List of Bertis’
oral presentations to be delivered at HUPO 2023(See the overview of
presentation details below)Seung-man Han, CEO of
Bertis, said, “It is encouraging for the Korean proteomics industry and
academia that the representative academic event in the proteomics field is held
in Korea at this critical juncture when the use cases of proteomics technology
are rapidly increasing across all areas of the bio industry. Bertis will also
leverage the upcoming HUPO 2023 as an opportunity to introduce Korea's
technologies to the global proteomics community and make its utmost efforts to
contribute to substantial breakthroughs in the development of proteomics
technology.Bertis plans to focus
on promoting protein data analysis and interpretation capabilities, as well as know-how
in technological commercialization through HUPO 2023. The company will set up a
large promotional booth inside the conference hall to introduce nine core
technologies related to biomarker discovery and algorithm development,
diagnostic service commercialization, and advanced technology. The primary focus
will be on the core technology framework ‘ProteoID(Proteome Integrated
Determination)’. Furthermore, it will publicize its pipeline of multi-marker
solutions for early diagnosis, including ‘MASTOCHECK®’, an early
diagnosis blood test for breast cancer, and PASS (Pan-omics Analysis Service
& Solution).
<Image>
ProteoID, Bertis’ core technology system, and nine essential technologiesThe name ProteoID is
derived from the term 'proteoid roots,' which refers to the densely packed
roots of plants. It implies the interactions among proteins, combinations of
various disease markers, and the organic blend of proteomics technologies.
Bertis is fully committed to realizing the potential of proteomics in clinical
and medical contexts based on ProteoID, a technology system that encompasses
all stages of utilizing proteomics technology, from protein data analysis to
product and service commercialization.